Abstract: Retinoblastoma is a rare cancer in children, where in less than a century of dire mortality there has been a cure in industrialized countries. Unfortunately, mortality remains high in emerging countries. The evolution of treatment makes it possible to go further by preserving the eyeball but this must not be done at the cost of the reappearance of metastases. Herein we outline the evolution of treatment from the beginning of the 20th century until the last recent evolutions, trying to imagine what could be the future treatments. In this pathology, the ophthalmologist is a doctor who must cure his patient and enucleation is considered a failure. This situation should not lead to shizophrenic situations where to keep an eye one would take risks with the life of the child. New international classifications, international prospective multicentric studies, and the search for blood biomarkers that can predict the risk of micrometastases could allow for better stratification of patients.
R
etinoblastoma is the most common malignant intraocular tumor in children but nevertheless remains a rare tumor, with an estimated incidence of 1/20,000 live births. Retinoblastoma is the first tumor for which a genetic origin was demonstrated.
1 According to the Knudson hypothesis, retinoblastoma carcinogenesis is related to a mutation on the 2 alleles of the RB1 tumor suppressor gene situated on chromosome 13q14.2. 2 The tumor can arise in a child carrying a germline mutation on 1 of the 2 alleles. A second hit mutation of the other allele in a precursor cell, the origin of which has not yet been clearly determined (cone precursor, retinal stem cells?), is responsible for the appearance of a retinal tumor. 3 This predisposition can be transmitted by a parent carrying the mutation (familial forms) or can occur as a de novo event. In this setting, retinoblastoma is usually bilateral or unilateral multifocal and the child is at risk of developing other extraocular tumors (soft tissue sarcoma, osteosarcoma, carcinoma, high-grade glioma, malignant melanoma).
4-6 Treatment must take into account the risk of developing second tumors, which can be increased by treatment with mutagenic agents (chemotherapy), X-rays, and radiotherapy. Retinoblastoma occurs almost exclusively in children under the age of 15 years and the median age at diagnosis is younger for the bilateral form (<12 months) than for the unilateral unifocal form (24 months). Early diagnosis is a priority, as it allows the child to be cured with preservation of almost normal vision in at least 1 of the 2 eyes. However, despite the well-known clinical signs, retinoblastoma is still often diagnosed at an advanced stage, requiring aggressive therapy with a high risk of enucleation of the affected eye in unilateral forms and 1 of the 2 eyes in bilateral forms and/or low vision after conservative treatment. Information campaigns directed to pediatricians and the general public and the development of smartphone applications to detect leukocoria remain insufficient in most countries.
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Diagnosis
The clinical presentation of retinoblastoma is well known. Leukocoria is the presenting sign in 60% of cases, but it is often a late sign and, when it is ignored by ophthalmologists, pediatricians, or general practitioners, retinoblastoma will only be diagnosed at an advanced stage, preventing globe-conserving treatment or requiring aggressive therapy with severe visual disability in bilateral forms. The second most common early sign of retinoblastoma is strabismus, generally related to a macular tumor. Provided this strabismus is not confused with accommodative strabismus, leading to delayed diagnosis, treatment can cure the child and allow preservation of the eye.
8 Less common clinical presentations may also be observed, generally indicating advanced forms (buphthalmia, neovascular glaucoma, orbital inflammation, phthisis bulbi, etc.), which generally do not allow globe-conserving treatment.
11
CliniCal Presentation
The clinical presentation varies according to the stage of the disease and the presence of 1 or several tumors in 1 or both eyes, with symmetrical or asymmetrical lesions. The tumor is visible as a white retinal mass with a variable blood supply depending on the size of the tumor and may present calcifications. The tumor or tumors may present as an endophytic form, in which the tumor extends into the vitreous; an exophytic form, associated with retinal detachment and subretinal infiltration; or a mixed form, comprising vitreous involvement and retinal detachment. Rarer clinical forms, such as diffuse infiltrating retinoblastoma (vitreous infiltration, hypopyon, and diffuse infiltration of the retina), must be recognized to avoid mistakes (diagnosis of uveitis, vitreous biopsy) that could have a catastrophic impact on survival. 12, 13 Retinoma (or retinocytoma) is a spontaneously arrested or spontaneously regressive form that resembles treated retinoblastoma with a grayer color, intense calcification, and a zone of atrophy around the lesion. These lesions can be detected on ocular fundus examination of a parent of a child with retinoblastoma or in a child consulting for leukocoria or strabismus. These lesions must be carefully monitored in young children, as they can progress to active retinoblastoma. 14, 15 There are also several well-known differential diagnoses (Coats disease, persistent hyperplastic primary vitreous, medulloepithelioma, uveal melanoma in children, retinal detachment due to other causes, Toxocara canis infection, etc.). 16 Examination in a reference center and modern imaging comprising duplex Doppler ocular ultrasound and magnetic resonance imaging (MRI) allow confirmation of the diagnosis in the great majority of cases. When there is a persistent doubt concerning an eye with no visual potential, enucleation is preferable to letting a retinoblastoma progress untreated. The child's parents must obviously be clearly informed.
Several classifications have been proposed to address various issues, but none of them are perfect. The first classification proposed by Reese-Ellsworth was developed in the age of external beam radiotherapy to evaluate the chances of globe-conserving radiotherapy. 17 This classification is now obsolete because, as we will see below, external beam radiotherapy must be avoided as far as possible. The second classification, the International Intraocular Retinoblastoma Classification (ABC classification), was developed by Murphree in 2005 in the age of systemic chemotherapy. This classification, ranging from A to E, can be used to estimate the possibility of preserving the eye by systemic chemotherapy in combination with local therapy. 18 However, this classification is also starting to become obsolete due to recent progress in local therapy. For example, group D, considered to be at high risk of enucleation due to extension of the tumor to the vitreous (even when only localized), is no longer systematically an obstacle to globe-conserving treatment as a result of the rapid progress in intravitreal chemotherapy. Nevertheless, this classification remains widely used. The new TNM classification (eighth American Joint Committee on Cancer TNM classification) estimates survival and the chances of preserving the eye by taking into account clinical risk factors (cT), histological risk factors (pT), the presence or absence of a germline mutation (H), and of course the presence of lymph node (N) or distant metastasis (M). Modern MRI imaging is also used for intraorbital and central nervous system staging. 3, 19, 20 History of treatment for retinoblastoma It is interesting to review the history of treatments for retinoblastoma to more clearly understand new treatments and their possible consequences. Before the beginning of the 20th century, despite improvement of enucleation techniques that were first proposed in the 16th century, a child with retinoblastoma had little chance of surviving. In 1895, Wilhelm Conrad Röntgen projected electrons accelerated by an electrical field onto a tungsten target in a vacuum tube, resulting in the emission of radiation, which he called X-rays due to its unknown nature. Radiology was born and radiology departments were first installed in hospitals in 1897. In 1896, Henri Becquerel reported, for the first time, a phenomenon that was subsequently called natural radioactivity by Marie Curie, who, in 1898 in collaboration with Pierre Curie, discovered the properties of radium and polonium, for which the couple was awarded the Nobel prize. After the Second World War, Marie Curie and Dr. Claudius Regaud founded the Institut Curie, devoted to the treatment of cancer. X-ray and radium treatments rapidly spread throughout the Western world and Soviet Union to treat all sorts of diseases, not just cancer. Radiotherapy was first used to treat a glioma of the retina (old name for retinoblastoma), probably using X-rays, the only modality available at the time, in the United States by Henry Louis Hilgartner. 12 The doses and fractionation of X-ray beam radiotherapy were formalized by Reese in 1936: 8000 rad per field fractionated by 400 rad per session (ie, a total dose of 16,000 rad). 21 In a series of 53 cases treated by the Reese protocol and published in 1949, survival had clearly improved to 74%. The indications consisted of enucleation of the more severely affected eye and irradiation of the other eye in the presence of visual potential and when the tumor or tumors were not too advanced (tumor not involving more than one fourth of the retinal surface, not too thick, and with limited vitreous invasion).
17 In addition to the ocular and cosmetic complications, several cases of sarcoma in the irradiated territory were first described in 1953.
21-23
The immense progress in retinoblastoma cure rates, with 5-year survival rates as high as 98% in industrialized countries, is due to several factors. The first factor, chemotherapy, was discovered by chance. During the Second World War, it was found that people exposed to nitrogen mustard developed low white blood cell counts, which led physicians to examine whether mustard agents could be used to stop cell division, for example, of cancer cells. Many drugs were rapidly discovered and used in the treatment of cancer. First-line chemotherapy, introduced in the 1990s, allowed intraocular tumor reduction and treatment of micrometastases, thereby decreasing mortality and increasing eye preservation rates. 24 Chemotherapy was also shown to be effective in the treatment of extraocular forms and trilateral forms (retinoblastoma associated with pinealoma). 25, 26 Several types of drugs were used but the most commonly used combination was vincristine, carboplatin, and etoposide. Depending on the severity, patients with bilateral retinoblastoma can be treated with a combination of 3 drugs or 2 drugs. A prospective randomized trial showed that the vincristine-carboplatin combination was slightly more effective than the etoposide-carboplatin combination.
27 Disseminated metastatic disease or cerebral involvement (pinealoma or metastases via the optic tract) requires intensive chemotherapy with autologous bone marrow transplantation. 25, 28 Cerebral involvement is associated with a poorer prognosis.
The second factor that has improved survival and eye preservation rates is the use of local therapy. Most teams specialized in the treatment of retinoblastoma agree that chemotherapy alone cannot ensure perfect control of intraocular disease but must be combined with local therapy (diode laser transpupillary thermotherapy, laser, cryoapplication, brachytherapy). Early diagnosis, as a result of information campaigns directed to the general population, healthcare professionals, and ophthalmologists, allows ablation of small tumors exclusively by local therapy or a combination of carboplatin and transpupillary thermotherapy. Local therapies can also be also used as second-line treatment for local relapse.
13,29
The third very important factor in improved patient survival, which must remain the primary objective, and eye preservation is the creation of specialized centers in various Western countries, comprising a multidisciplinary team composed of ophthalmologists, oncologists, pediatric oncologists, radiation physicians, radiologists, geneticists, anesthetists, and so on.
30
This high level of multidisciplinary competence allows tailored treatments based on the findings of the initial ophthalmological examination, which must be performed under general anesthesia. In other rare cancers, such as sarcomas, an international expert group has established that patient survival is influenced by management in reference centers and has established the essential requirements in terms of multidisciplinarity and quality of care for a center to be considered as a reference center.
31 A similar study probably needs to be conducted for retinoblastoma.
1 In centers treating retinoblastomas, genetic information concerning the parents of an affected child and patients treated for retinoblastoma during childhood is essential and germline mutation screening must be systematically proposed, without neglecting mosaic phenomena. 32 In countries in which the 5-year survival rates of bilateral retinoblastoma exceed 98%, and as chemotherapy is now associated with a low risk of infertility, the number of familial cases will probably increase considerably. Genetic information and the earliest possible screening of descendants of survivors during the first week of life or, according to some authors, even prenatal screening, will also increase survival, eye preservation rates, and visual acuity.
33
Currently available treatments
Chemotherapy
Various drugs are used for intravenous, intra-arterial, subconjunctival, or intravitreal chemotherapy depending on the team (most commonly carboplatin, vincristine, etoposide, topotecan, melphalan). Chemoreduction followed by local therapy is still widely used by many teams with recognized efficacy and acceptable systemic toxicity.
34,35
The intra-arterial route of administration developed by Kaneko, using melphalan or topotecan or carboplatin alone or in combination, allows drug administration directly into the ophthalmic artery, thereby limiting systemic distribution of chemotherapy and its adverse effects.
36 Consequently, local administration cannot be used to treat micrometastases in advanced forms of the disease. This route of administration is not devoid of local toxicity on the choroidal and retinal blood supply and must be performed by an experienced team of neuroradiologists. 37 In a large metaanalysis based on 208 publications on the subject, only 28 articles with sufficient follow-up could be analyzed. Most of these studies were retrospective and noncomparative. Enucleation was avoided in 66% of cases and 20 cases of metastases were reported. These cases of metastases probably occurred in the context of treatment of advanced retinoblastoma. 38 Nevertheless, this treatment is very effective in unilateral forms with visual potential (cT2 or group C or D). Some authors also use intra-arterial chemotherapy to treat bilateral forms. 39 The place of this treatment remains controversial in advanced unilateral forms (cT3 or V) regardless of the subgroup in the absence of visual potential. No clear consensus has been reached, as the indications for intra-arterial chemotherapy vary from one team to another. 38, 40, 41 No multicenter prospective studies comparing intra-arterial chemotherapy and systemic chemotherapy are available and the published studies are all too often retrospective and present excessive bias to allow reliable scientific results. There is also insufficient follow-up concerning the sensitivity of bone and soft tissues to repeated exposure to low doses of X-rays necessary for catheter positioning by radiologists: these doses are not negligible in the context of constitutional alteration of the RB1 gene, associated with an increased risk of second tumor (essentially sarcoma) in the irradiated field.
Intravitreal administration of melphalan or topotecan is a particularly effective treatment for vitreous seeding. This treatment has been described by several teams and was formalized by Munier et al. 42 A rigorous technique is essential due to the risk of tumor cell dissemination along the needle track. 43 Some cases of extraocular tumor spread have been described. 44 This phenomenon is probably rare, but several cases that have been reported to the author have never been published. Francis et al 45 developed a classification of vitreous seeds (dust, sphere, clouds) to estimate the number of injections required to sterilize the vitreous. 45 Local vascular complications have also been described and are more frequent when intravitreal chemotherapy is performed as salvage therapy in a multitreated globe or concomitantly with intraarterial chemotherapy. 46, 47 Compliance with the most commonly accepted doses (20-30 µg of melphalan) is important to avoid major complications, including phthisis bulbi for doses higher than 50 µg.
radiotherapy
External beam radiotherapy (EBRT) is now more rarely used due to the risk of local complications and the major risk of sarcoma in the irradiated field. The incidence of second cancer in the irradiated field, but also outside of the irradiated field, was estimated to be 51% at 50 years by a team in New York on the basis of a very large series. 49 Radiotherapy is almost no longer used in countries in which other forms of salvage therapy are available (intra-arterial chemotherapy, intravitreal chemotherapy, brachytherapy), but is still used in countries in which only this treatment modality is available. A recent study also showed a second cancer rate of 35% 40 years after the diagnosis of retinoblastoma. This incidence depends on the type of treatment: 3.4% for children exclusively enucleated without chemotherapy or radiotherapy, 3% for patients treated by systemic chemotherapy, and up to 20% for patients treated by EBRT (usually sarcomas in the irradiated field). In this study, brachytherapy or systemic chemotherapy without external beam radiotherapy did not increase the incidence of second cancers. Brachytherapy was developed by Henry Stallard, initially using radium then cobalt plaques, in the 1930s and was subsequently refined by the use of iodine 125 or ruthenium plaques. It is generally used for peripheral tumors and usually as second-line treatment. Orbital brachytherapy using rows of iodine 125 plus a plaque can be used instead of EBRT after enucleation in the presence of extraocular tumor spread or positive optic nerve resection margins (pT4), in combination with systemic chemotherapy.
50,51
other focal treatments Triple freeze-thaw cryotherapy with freezing as far as the tip of the tumor is used for peripheral tumors inaccessible to laser ablation not exceeding a thickness of several millimeters.
Laser thermotherapy is used as an adjuvant to chemotherapy or alone for small tumors or localized relapses and consists of administering a dose of 550 mg/m 2 of carboplatin followed by diode laser thermotherapy with a 1.2-mm spot and a mean power of 500 mW. 52 treatment strategies first-line treatment dilated ocular fundus examination under general anesthesia, MRI, and a pediatric assessment, is essential before any treatment decisions and should be done in emergency.
53
Hereditary form of the tnm Classification; familial forms and bilateral retinoblastomas 19 Genetic information is essential in familial forms. Prenatal diagnosis must be proposed to the parents, and therapeutic termination of pregnancy should be proposed when necessary but without influencing the parents' decision. Embryo selection and in vitro fertilization of embryos not carrying a constitutional alteration of the RB1 gene is possible in some countries. Parents must be informed about this possibility. If, for moral, ethical, or religious reasons, the parents decide to refuse prenatal diagnosis or continue the pregnancy, their decision must obviously be respected. A child born to a parent with a history of retinoblastoma must be examined during the first week of life and, in the absence of visible tumor, must be examined at least monthly under general anesthesia.
54 Small cT1a tumors detected on clinical examination or optical coherence tomography can be treated by transpupillary thermotherapy alone. In contrast, more advanced cT2 forms should be treated by a combination of carboplatin and transpupillary thermotherapy. The treatment most commonly proposed for more advanced lesions or asymmetrical forms in which 1 of the eyes presents an advanced stage cT3 lesion is a combination of systemic chemotherapy including 2 or 3 drugs and local therapy. 27, 35, 55, 56 Transpupillary thermotherapy in combination with chemotherapy must be applied to the tumor, while sparing the macula.
57
Patients with nonfamilial bilateral forms are often diagnosed at a more advanced stage, at least for 1 of the 2 eyes. The treatment usually proposed is systemic combination chemotherapy (2 or 3 drugs depending on the case) and local therapy.
13,35 Some teams propose bilateral intra-arterial chemotherapy, 39 but this method may fail to treat any micrometastases.
unilateral retinoblastoma
Paradoxically, the treatment of unilateral retinoblastoma remains highly controversial. Unilateral retinoblastoma discovered in a very young child before the age of 2 years must be treated very cautiously due to the possibility of an H1 hereditary form and the risk of retinoblastoma arising in the other eye in the months after diagnosis (metachronous form). The approach to the affected eye would tend to be more conservative in H1 children, except in the presence of very advanced disease (cT3 or cT4). Unilateral forms occurring in older patients are associated with a higher probability of H0 status. In this case, the benefits of aggressive therapy, with its impact on the child's quality of life and on organization of family life, must be weighed against the chances of conserving an eye with no visual potential and the nonnegligible risk of micrometastases.
58 Preservation of a cT3 (V) eye has major consequences for the child and is associated with a risk of metastasis.
59 Magnetic resonance imaging can provide arguments in favor of the metastatic risk (retrolaminar invasion, massive choroidal invasion). 53 Parents correctly informed about the benefits of conserving a nonfunctional eye and intensive eyeconserving treatment, which is not always successful and which is associated with a non-negligible risk of metastases, usually accept enucleation because their priority as parents is to save their child's life. Moreover, the cosmetic results of enucleation with placement of an integrated hydroxyapatite implant are more satisfactory than the presence of a hypotrophic eyeball, strabismus, or phthisis bulbi. In some cases of very high intraocular pressure with buphthalmos, neoadjuvant chemotherapy is sometimes necessary to perform enucleation under the best possible conditions. In every case, the optic nerve must be sectioned as far away from the globe as possible to obtain 10 to 11 mm of optic nerve. In this particular case, as neoadjuvant chemotherapy may mask risk factors for metastasis, chemotherapy should be continued postoperatively. 60, 61 Preoperative MRI must be performed before enucleation to assess potential optic nerve invasion or the presence of extraocular tumor spread in very advanced cases. 53, 62 Histological examination of the entire globe according to the methodology defined by the Royal College of Pathologists (www.rcpath.org) must then be rapidly performed to confirm the diagnosis and assess histological risk factors. 19, 63 The new TNM classification redefines the importance of analysis of choroidal invasion: invasion less than 3 mm is associated with an estimated risk of metastasis between 0 and 1%, this risk increases to 3% for invasion greater than 3 mm, and when invasion involves the sclera, the risk of metastasis is 5%. Analysis of the optic nerve is also important, as retrolaminar involvement is a risk factor for metastasis, and positive optic nerve resection margins and meningeal sheath invasion are associated with poor prognosis. Adjuvant chemotherapy is indicated in the presence of risk factors for metastasis.
19,61 Positive optic nerve resection margins require, in addition to chemotherapy, complementary orbital radiotherapy either in the form of orbital brachytherapy or conventional external irradiation.
64 Less advanced retinoblastomas presenting visual potential and in the absence of optic nerve invasion (cT1, cT2; ie, groups A, B, C, and some cases of group D) can be treated conservatively by thermochemotherapy or chemoreduction by carboplatin-etoposide or vincristine-carboplatin or by intra-arterial chemotherapy and local therapy, as described above. Localized vitreous invasion is no longer an obstacle to conserve an eye with the availability of intravitreal chemotherapy. Cases of massive vitreous invasion with a risk of orbital dissemination along the needle track must be treated cautiously. 44 Intravitreal chemotherapy may be responsible for retinal and more rarely anterior segment toxicity. This toxicity increases with the number of injections and the concomitant administration of intra-arterial chemotherapy.
surveillance and salvage therapy
There is a high risk of relapse or second tumor after stopping first-line treatment. Patients must be reviewed at least monthly with examination under general anesthesia by indenting the periphery with wide-field photography for 6 months, then every 3 months. Any new lesions detected in time can be treated by local therapy. Patients with massive relapse not amenable to local therapy must be discussed in a multidisciplinary consultation meeting. Massive unilateral relapse in a nonfunctional eye, depending on the state of the other eye, can be treated by either enucleation or, when possible (eye with preserved visual potential), a combination of carboplatin chemotherapy and transpupillary thermotherapy, or a combination of intra-arterial and intravitreal chemotherapy in the case of vitreous relapse, or brachytherapy.
in an industrialized country, it is only reasonable to consider the possibility of treatment de-escalation, but unfortunately this is not an issue in developing countries where mortality remains high.
65,66 Treatment de-escalation comprises less frequent use of external beam radiotherapy and the development of regional and local therapies to limit the use of systemic chemotherapy. It is also logical to try to conserve the eyeball and vision whenever possible, but never at the price of an increased risk of metastasis. Considerable progress has already been made, but a marker able to predict the risk of metastasis as effectively as histological examination of the eyeball while conserving the same needs to be developed. Although increasingly efficient, MRI is still unable to accurately assess choroidal involvement. 53 The key to staging patients at high risk of micrometastasis will probably be based on circulating biomarkers. One possibility is the detection of microRNAs.
67 Cone-rod homebox (CRX) and Otx-like homebox transcriptor for photoreceptor transcription have been reported as potential biomarkers. 68 More recently, one study showed that CTX messenger RNA is also a promising marker for the detection of micrometastasis. 59 Hopefully, in the fairly near future, biomarkers will be able to predict the risk of micrometastases and allow treatment de-escalation with minimal risks for patients.
